Document is current
Any future updates will be listed below
-
Authors
Kato, Chris
Ueda, Koji
Morimoto, Satoru
Takahashi, Shinichi
Nakamura, Shiho
Ozawa, Fumiko
Ito, Daisuke
Daté, Yugaku
Okada, Kensuke
Kobayashi, Naoki
Nakahara, Jin
Okano, Hideyuki https://orcid.org/0000-0001-7482-5935
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (JP21H05278, JP22K15736, JP22K07500, JP20H00485)
Japan Agency for Medical Research and Development (JP22ek0109616, JP23bm1123046, JP23kk0305024, JP21wm0425009, JP22bm0804003, JP22ek0109616, JP23bm1423002)
Miyata Yukihiko Memorial ALS Research Grant Foundation
Yoshio Koide Grant, Japan ALS Association
Daiichi Sankyo Foundation of Life Science
UBE Academic Foundation
- License Information
-
More Information
Article History
Received: 3 April 2024
Accepted: 26 June 2024
First Online: 12 July 2024
Declarations
:
: This study was approved by the Institutional Review Board of Keio University Hospital (approval No. D18-01) and Keio University School of Medicine (approval No. 20080016), and written informed consent was obtained from the participants. The use of NCNP Biobank samples was approved by the utilization committee (No. NCNPBB-0132) and the ethics committee of the National Center of Neurology and Psychiatry (No. A2012-091).
: Not applicable.
: HO reports grants and personal fees from K Pharma, Inc. during the conduct of the study; personal fees from Sanbio Co. Ltd., outside the submitted work. In addition, HO has a patent on a therapeutic agent for amyotrophic lateral sclerosis and composition for treatment licensed to K Pharma, Inc. The other authors have declared that no conflict of interest exists.
